Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex

Psychopharmacology
Mei HuangHerbert Y Meltzer

Abstract

A typical antipsychotics (APDs), e.g. olanzapine and risperidone, have been reported to be effective adjunctive treatment for depression if selective serotonin (5-HT) reuptake inhibitors (SSRIs) alone are ineffective. We utilized microdialysis in awake, freely moving rats to study the effect of risperidone in combination with citalopram, an SSRI, on extracellular 5-HT, dopamine (DA), and norepinephrine (NE) efflux in rat medial prefrontal cortex (mPFC). Risperidone (1.0 mg/kg, s.c.), given alone, significantly increased 5-HT, DA, and NE concentrations in the mPFC. Citalopram (10 mg/kg, s.c.), by itself, produced a significant increase in 5-HT levels only. The combination of risperidone and citalopram produced significantly greater increases in efflux of both DA and NE than risperidone alone. However, the effect of this combination on extracellular 5-HT concentrations was not significantly different than that of citalopram alone. The augmentation of DA and NE efflux induced by risperidone plus citalopram could be partially blocked by the selective 5-HT1A antagonist, WAY 100635 (0.2 mg/kg, s.c.). The results suggest that the ability of atypical APDs to augment the therapeutic efficacy of SSRIs in major depression and treatment-re...Continue Reading

References

Jan 1, 1990·Progress in Neuro-psychopharmacology & Biological Psychiatry·F P Zemlan, D L Garver
Jan 1, 1990·Annals of the New York Academy of Sciences·H Y Meltzer
Oct 1, 1986·Physiology & Behavior·J P Kroon, A L Riley
Jun 1, 1996·The Psychiatric Clinics of North America·M Fava, K G Davidson
Jun 1, 1996·The Psychiatric Clinics of North America·J D Amsterdam, M Hornig-Rohan
Jul 1, 1997·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·P HertelT H Svensson
Feb 24, 1998·Journal of Clinical Psychopharmacology·M O'Connor, H Silver
Apr 30, 1999·The Journal of Clinical Psychiatry·R B Ostroff, J C Nelson
Apr 27, 2000·European Journal of Pharmacology·K HatanakaT Yamaguchi
Apr 27, 2000·European Journal of Pharmacology·K HatanakaT Yamaguchi
Aug 5, 2000·Journal of Clinical Psychopharmacology·A L Stoll, G Haura
Aug 16, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·W ZhangF P Bymaster
Jan 4, 2001·The American Journal of Psychiatry·R C SheltonH Y Meltzer
Sep 12, 2001·The Australian and New Zealand Journal of Psychiatry·G Parker, G Malhi
Dec 26, 2001·Annual Review of Psychology·Richard J DavidsonKatherine Putnam
Mar 5, 2002·The Journal of Clinical Psychiatry·Michael E Thase
Aug 17, 2002·The Journal of Pharmacology and Experimental Therapeutics·Steven T Szabo, Pierre Blier
Aug 29, 2002·The Journal of Clinical Psychiatry·Shigehiro Hirose, Charles R Ashby
Dec 5, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Susanne KochFrank P Bymaster

❮ Previous
Next ❯

Citations

Dec 21, 2010·Psychopharmacology·Parichehr Hassanzadeh, Sina Rahimpour
Sep 23, 2010·Neurocase·Edward C LauterbachLauren L Greenway
Oct 19, 2007·Proceedings of the National Academy of Sciences of the United States of America·Yasin TemelTrevor Sharp
Mar 15, 2012·International Journal of Psychiatry in Clinical Practice·Nienke C C VulinkDamiaan Denys
Aug 25, 2012·Expert Opinion on Investigational Drugs·Gaël QuesseveurBruno P Guiard
Feb 24, 2012·Pharmacological Reports : PR·Zofia Rogóż, Marcin Kabziński
Apr 27, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Corina O BondiDavid A Morilak
Jan 2, 2010·Behavioural Brain Research·Trisha A JenkinsStephen J Cooper
Dec 30, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Matthijs G P FeenstraDamiaan Denys
Jul 29, 2010·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Louise M PatersonGitte M Knudsen
Jun 19, 2010·CNS Neuroscience & Therapeutics·Giuseppe Di GiovanniVincenzo Di Matteo
Oct 29, 2013·Pharmacology, Biochemistry, and Behavior·Olivia F O'LearyJohn F Cryan
Nov 9, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Carmine TomasettiAndrea de Bartolomeis
Aug 1, 2014·Behavioural Brain Research·Davide Amato
Jul 10, 2013·European Journal of Pharmacology·Andrea de BartolomeisCarmine Tomasetti
Oct 19, 2016·Pharmacological Reports : PR·Katarzyna KamińskaKrystyna Gołembiowska
Feb 17, 2018·Pharmaceutical Research·Willem Johan van den BrinkElizabeth Cunera Maria de Lange
Oct 10, 2013·Nature Reviews. Neuroscience·R James R Blair
Sep 2, 2008·Expert Review of Neurotherapeutics·Seetal Dodd, Michael Berk
Mar 19, 2020·Evidence-based Complementary and Alternative Medicine : ECAM·Yuan DuFenghua Fu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here